Wealth Enhancement Advisory Services LLC Grows Position in Encompass Health Co. (NYSE:EHC)

Wealth Enhancement Advisory Services LLC boosted its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 46.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,204 shares of the company's stock after purchasing an additional 6,053 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Encompass Health were worth $1,774,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of EHC. abrdn plc purchased a new stake in Encompass Health in the fourth quarter worth about $17,846,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Encompass Health by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 769,716 shares of the company's stock valued at $71,083,000 after purchasing an additional 2,904 shares during the period. Fairvoy Private Wealth LLC bought a new stake in shares of Encompass Health during the 4th quarter valued at $208,000. Lecap Asset Management Ltd. purchased a new position in Encompass Health during the fourth quarter valued at $1,314,000. Finally, Apollon Wealth Management LLC grew its stake in Encompass Health by 7.3% during the fourth quarter. Apollon Wealth Management LLC now owns 2,856 shares of the company's stock valued at $264,000 after acquiring an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 97.25% of the company's stock.

Encompass Health Stock Up 0.2%

Shares of Encompass Health stock traded up $0.28 on Friday, reaching $121.57. The stock had a trading volume of 406,135 shares, compared to its average volume of 700,185. The company has a 50 day moving average price of $111.96 and a 200 day moving average price of $102.74. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 1 year low of $82.74 and a 1 year high of $123.13. The stock has a market capitalization of $12.25 billion, a P/E ratio of 27.26, a P/E/G ratio of 2.31 and a beta of 0.89.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.18. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. Encompass Health's revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.12 EPS. As a group, equities research analysts forecast that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.56%. The ex-dividend date is Tuesday, July 1st. Encompass Health's payout ratio is 14.05%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on EHC shares. Wall Street Zen cut shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday. KeyCorp raised their target price on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a report on Tuesday, May 27th. Truist Financial restated a "buy" rating and issued a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Barclays lifted their price objective on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, UBS Group boosted their price target on shares of Encompass Health from $117.00 to $130.00 and gave the company a "buy" rating in a report on Monday, April 28th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $127.00.

Insider Buying and Selling at Encompass Health

In related news, EVP John Patrick Darby sold 10,000 shares of the business's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the completion of the transaction, the executive vice president now directly owns 79,710 shares in the company, valued at $9,149,910.90. The trade was a 11.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the company's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total transaction of $498,974.19. Following the transaction, the insider now owns 11,958 shares of the company's stock, valued at $1,394,422.38. This represents a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 132,663 shares of company stock worth $16,034,082. Company insiders own 2.10% of the company's stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.